Heartland Bank & Trust Co Has $4.12 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Heartland Bank & Trust Co lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,986 shares of the company's stock after purchasing an additional 340 shares during the period. Eli Lilly and Company comprises about 2.1% of Heartland Bank & Trust Co's investment portfolio, making the stock its 9th biggest position. Heartland Bank & Trust Co's holdings in Eli Lilly and Company were worth $4,118,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in LLY. Cyr Financial Inc. increased its stake in Eli Lilly and Company by 12.5% in the 1st quarter. Cyr Financial Inc. now owns 821 shares of the company's stock worth $678,000 after purchasing an additional 91 shares during the period. Matrix Asset Advisors Inc. NY boosted its stake in shares of Eli Lilly and Company by 12.6% during the first quarter. Matrix Asset Advisors Inc. NY now owns 340 shares of the company's stock valued at $281,000 after purchasing an additional 38 shares during the period. Rappaport Reiches Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 75.6% in the first quarter. Rappaport Reiches Capital Management LLC now owns 460 shares of the company's stock worth $380,000 after purchasing an additional 198 shares during the last quarter. Cullinan Associates Inc. increased its stake in shares of Eli Lilly and Company by 3.5% in the first quarter. Cullinan Associates Inc. now owns 9,370 shares of the company's stock worth $7,738,000 after buying an additional 315 shares during the period. Finally, Intact Investment Management Inc. increased its stake in shares of Eli Lilly and Company by 9.4% in the first quarter. Intact Investment Management Inc. now owns 2,670 shares of the company's stock worth $2,205,000 after buying an additional 230 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.79.

Eli Lilly and Company Stock Down 2.8%

Shares of NYSE:LLY opened at $763.43 on Friday. The firm has a market capitalization of $723.53 billion, a P/E ratio of 62.12, a P/E/G ratio of 1.11 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The stock has a 50 day moving average price of $780.48 and a 200-day moving average price of $800.93. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 earnings per share. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.